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Abstract
Background: To improve current treatment strategies for patients with aggressive colorectal cancer (CRC), the
molecular understanding of subgroups of CRC with poor prognosis is of vast importance. SOX2 positive tumors
have been associated with a poor patient outcome, but the functional role of SOX2 in CRC patient prognosis is still
unclear.
Methods: An in vitro cell culture model expressing SOX2 was used to investigate the functional role of SOX2 in
CRC. In vitro findings were verified using RNA from fresh frozen tumor tissue or immunohistochemistry on formalin
fixed paraffin embedded (FFPE) tumor tissue from a cohort of 445 CRC patients.
Results: Using our in vitro model, we found that SOX2 expressing cells displayed several characteristics of cancer
stem cells; such as a decreased proliferative rate, a spheroid growth pattern, and increased expression of stem cell
markers CD24 and CD44. Cells expressing SOX2 also showed down-regulated expression of the intestinal epithelial
marker CDX2. We next evaluated CDX2 expression in our patient cohort. CDX2 down-regulation was more often
found in right sided tumors of high grade and high stage. Furthermore, a decreased expression of CDX2 was
closely linked to MSI, CIMP-high as well as BRAF mutated tumors. A decreased expression of CDX2 was also, in a
stepwise manner, strongly correlated to a poor patient prognosis. When looking at SOX2 expression in relation to
CDX2, we found that SOX2 expressing tumors more often displayed a down-regulated expression of CDX2. In
addition, SOX2 expressing tumors with a down-regulated CDX2 expression had a worse patient prognosis
compared to those with retained CDX2 expression.
Conclusions: Our results indicate that SOX2 expression induces a cellular stem cell state in human CRC with a
decreased expression of CDX2. Furthermore, a down-regulated expression of CDX2 results in a poor patient
prognosis in CRC and at least part of the prognostic importance of SOX2 is mediated through CDX2 down-
regulation.
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Background
Colorectal cancer (CRC) is a common malignancy
worldwide and the second leading cause of cancer
deaths in the western world [1]. CRC is often detected at
late stages contributing to the high mortality rate seen in
this disease. Today, most patients receive a similar stage
specific treatment strategy, however not all benefit from
it. In future treatment of CRC patients, personalized
therapy will be of vast importance, but this will also
place higher demands on the molecular subclassification
of CRC.
The SOX2 gene encodes for a transcription factor and
is a member of the SRY-related HMG-box (SOX) gene
family. It is known that SOX2 plays essential roles in cell
fate determination, thereby regulating developmental
processes [2]. In recent years, aberrant expression of
SOX2 has been reported in CRC as well as several other
types of cancers [3–6]. According to our previous study,
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SOX2 expression was found to be correlated to high
tumor grade, mutated BRAF and a poor patient progno-
sis [7]. We further found that the expression of SOX2
was partly regulated by BRAF [7]. Expression of SOX2
has also been associated with distant metastases in right-
sided colon cancer [8], suggesting that SOX2 expressing
tumors represent a subgroup with poor patient outcome.
In CRC, SOX2 has previously been suggested to regulate
epithelial-mesenchymal transition (EMT) and increased
tumor migration and invasion [9]. However, the func-
tional role of SOX2 in CRC patient prognosis is still
unclear.
Recent research has revealed that a small subgroup of
tumor cells possesses characteristics associated with stem
cells and have therefore been called cancer stem cells
(CSCs). CSCs have the ability of self-renewal and multi-
lineage differentiation, features that can cause both tumor
growth and emergence of new tumors [10–12]. SOX2 ex-
pression has been associated with a stem cell state in hu-
man ovarian, cervical, pancreatic, head and neck
squamous cell, and breast carcinoma [3, 13–16], but so far
this has not been shown in CRC. SOX2 expression has
been associated with tumors of high grade (poorly differ-
entiated) in different cancers [7, 17–20]. The transcription
factor, Caudal type homeobox 2 (CDX2), is a major regu-
lator of the expression of intestine-specific genes involved
in cell differentiation [21, 22]. CDX2 is expressed at high
levels in the normal colorectal epithelium, but loss or de-
crease of expression is seen in a subset of CRCs [23, 24].
Previous studies have also reported that loss of CDX2 is
associated with poor patient prognosis in CRC [25–27].
In this study we investigated the functional role of
SOX2 in CRC using an in vitro cell culture model. We
found no evidence that SOX2 was involved in regulation
of EMT or cellular migration. However, SOX2 positive
cells were found to display several characteristics of can-
cer stem cells, as well as a decreased expression of the
intestinal epithelial marker CDX2. In a cohort of CRC
patients, we further demonstrate that SOX2 expression
is significantly associated with down-regulated expres-
sion of CDX2 and at least part of the prognostic import-
ance of SOX2 is mediated through CDX2 down-
regulation. In conclusion, we suggest that CDX2 down-
regulation is partly regulated by SOX2 and contributes
to a poor prognosis in this patient group.
Methods
Cell culture and cell lines
In this study, the human colon cancer cell lines Caco2,
SW480 and SW620 (American Type Culture Collection,
Manassas, VA, USA) were grown in Dulbecco’s modified
Eagle’s medium (DMEM) with glutamax supplemented
with 10 % fetal bovine serum (FBS) (Gibco, Life Technolo-
gies, Stockholm, Sweden) and maintained at 37 °C and
5 % CO2. The stable transfectant expressing increased
levels of SOX2 has been previously described [7].
Migration assay
Cell migration was analyzed using transwell cell culture
inserts with a pore size of 8 μm (BD Biosciences,
Stockholm, Sweden) in 24-well plates. Caco2 or Caco2-
SOX2 were seeded at a density of 1x105 per insert in cell
culture medium with 10 % FBS for 2–3 h. Media was
subsequently exchanged to serum-free DMEM and cells
were allowed to migrate towards either culture media
supplemented with 10 % FBS or serum-free medium for
20 h at 37 °C and 5 % CO2. Cells remaining on the in-
side of the insert were removed with cotton swabs and
the cells that migrated through the membrane were
fixed and stained with Coomassie blue (Bio-Rad Labora-
tories, Solna, Sweden). For quantification, three fields
were chosen randomly and migrating cells were counted
at x10 magnification using a light microscope. The ex-
periment was repeated three times.
Proliferation assay
Cell proliferation was assessed by the XTT assay (Roche
Diagnostics, Bromma, Sweden) according to the manu-
facturer’s instructions. In brief, Caco2 or Caco2-SOX2
cells were cultured in a 96-well plate at a density of
5x103 per well in cell culture media supplemented with
10 % FBS for 72 h at 37 °C and 5 % CO2. The cells were
then incubated with XTT labeling for 4 h at 37 °C before
the absorbance was measured with an ELISA reader at a
wavelength of 490 nm. A reference wavelength at
650 nm was also measured. Quadruplicates of each sam-
ple were analyzed and the experiment was repeated
three times.
Real time PCR
The NucleoSpin RNA kit (Macherey-Nagel, Duren,
Germany) was used for isolation of total RNA from cul-
tured cells, and cDNA was synthesized with the Super-
Script II Reverse Transcriptase (Invitrogen, Life
Technologies, Stockholm, Sweden). Fresh frozen human
tumor tissue was homogenized using the gentleMACS
Dissociator (Miltenyi Biotec, Bergisch Gladbach,
Germany) before total RNA was isolated with the High
Pure RNA Paraffin Kit (Roche Diagnostics, Stockholm,
Sweden) and then converted into cDNA using the
SuperScript VILO cDNA Synthesis Kit (Invitrogen, Life
Technologies, Stockholm, Sweden). All steps were per-
formed according to manufacturer’s protocols.
In the present study, primers for GAPDH, RPL13A,
SOX2, MMP3, MMP11, E-cadherin, Snail and Fibronec-
tin were from DNA Technology A/S (Aarhus, Denmark)
and their sequences are listed in Additional file 1. For
the remaining genes, Quantitect Primer Assays (Qiagen,
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Sollentuna, Sweden) were used. Quantitative RT-PCR re-
actions were performed on an ABI 7900HT instrument
(Applied Biosystems, Life Technologies, Stockholm,
Sweden) with the following thermal cycling conditions
used: 50 °C for 2 min and then an initial denaturation at
95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s
and 60 °C for 60 s. Gene expression was normalized to
GAPDH for cultured cells or RPL13A for fresh frozen
tumor specimens. Standard deviations were calculated
for the mean of triplicate reactions.
Clinical samples
CRC specimens included in this study were from the
Colorectal Cancer in Umeå Study (CRUMS) [28]. Tumor
tissue samples were collected from patients with primary
CRC that underwent tumor-resective surgery between
1995 and 2003 at Umeå University Hospital, Sweden.
Formalin-fixed paraffin-embedded (FFPE) tissue was
sampled from all patients and fresh frozen tumor tissue
was collected from a subgroup of the patients. One
pathologist did all histopathological classifications by
reviewing routinely stained tumor sections, as previously
described [28]. Clinical data were obtained from the pa-
tient records, and survival data was collected during au-
tumn 2012. 445 cases were included in this study, but
due to unavailable or insufficient tumor sample or nega-
tive staining in adjacent normal colon epithelium (n = 14),
431 of the tumors could be successfully analyzed for
CDX2 expression.
Analyses of microsatellite instability (MSI) screening
status, CpG island methylator phenotype (CIMP) status
and mutational status of BRAF and KRAS have previ-
ously been described [29, 30]. In brief, MSI screening
status was determined in FFPE tissue samples by immu-
nohistochemical analyses of the expression of four mis-
match repair proteins (MLH1, MSH2, MSH6 and
PMS2). Tumors lacking nuclear staining for at least one
of the four proteins were considered to have a positive
MSI screening status, compared to those with a negative
MSI screening status, referred to as microsatellite stable
(MSS). CIMP status was determined by the MethyLight
method with previously described primer and probe se-
quences. An eight gene panel (CDKN2A, MLH1, CAC-
NA1G, NEUROG1, RUNX3, SOCS1, IGF2, and CRABP1)
was used for evaluation of the hypermethylation status:
CIMP-negative tumors (no promoter hypermethylation),
CIMP-low tumors (one to five genes methylated) or
CIMP-high tumors (six to eight genes methylated).
BRAFV600E mutation was detected by the Taqman allelic
discrimination assay [31] (reagents from Applied Biosys-
tems, Life Technologies, Stockholm, Sweden). KRAS
mutational status was determined by sequencing using
Big Dye v. 3.1 (Applied Biosystems, Life Technologies,
Stockholm, Sweden). The expression of SOX2 has
previously been evaluated in this patient cohort [7],
where nuclear staining was assessed as either negative or
positive.
Immunohistochemistry
FFPE CRC specimens were cut at 4-μm and then dried,
deparaffinized and rehydrated. CDX2 mouse monoclonal
antibody (clone CDX2-88, Biogenex, Fremont, CA,
USA) was used at a dilution of 1:50 and visualized by
the iVIEW DAB Detection kit on an Ventana Bench-
mark Ultra staining machine (Ventana Medical Systems,
Tucson, AZ, USA), with the CC1 standard pretreatment.
Normal colon mucosa was used as positive control. The
slides were counterstained with hematoxylin. Immuno-
histochemical staining of CDX2 was evaluated under
light microscopy by one observer two times under
supervision of an experienced pathologist. In cases with
discrepant scoring, a third final evaluation was made.
Nuclear CDX2 staining was scored as: <5 % positive
tumor cells, 5-50 % positive tumor cells or >50 % posi-
tive tumor cells. Normal colon mucosa, if included in
the sample, was used as an internal positive control.
Statistical analyses
IBM SPSS Statistics software version 21 (SPSS Inc., Chi-
cago, Illinois, USA) was used for statistical analyses. The
nonparametric Mann–Whitney U-test was performed in
order to compare the differences in gene expression
levels between two groups. Cross-tabulations for associa-
tions between CDX2 expression and different clinico-
pathological and molecular variables were analyzed with
χ2 tests. To estimate cancer-specific survival, Kaplan-
Meier survival analysis was used, and the log-rank test
was used for comparisons between groups. Cancer-
specific survival was defined as death with known dis-
seminated or recurrent disease. Patients lacking survival
data or patients who died with postoperative complica-
tions within one month after surgery (n = 34) were ex-
cluded from the survival analyses. For multivariable
analyses, Cox proportional hazard models were used. P
< 0.05 was considered statistically significant for all
analyses.
Results
To gain mechanistic insights to the prognostic import-
ance of SOX2 in CRC, we created a stable transfectant
of the CRC cell line Caco2 expressing increased levels of
SOX2 (Caco2-SOX2) as previously described [7]. The
Caco2 cell line was chosen to represent one of the lar-
gest subgroups of sporadic CRCs; CIMP negative, MSS
and wild-type in KRAS and BRAF [32].
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SOX2 is not a major regulator of EMT and cellular
migration in CRC cells
In CRC, SOX2 has previously been linked to EMT and in-
creased migration and invasion [9]. EMT is linked to
changes in expression of several transcription factors and
cellular adhesion molecules. To investigate these events in
our in vitro model, we compared the expression of EMT
related factors in Caco2 and Caco2-SOX2 cells. Even
though the epithelial marker E-cadherin (CDH1) was
found to be significantly decreased by SOX2, the expres-
sion of the transcription factors Snail (SNAI1), Slug
(SNAI2) and Twist1, controlling E-cadherin expression
were unaltered or decreased (Fig. 1a). Furthermore, ex-
pression of Fibronectin, N-cadherin and Vimentin, associ-
ated with a mesenchymal phenotype, were not increased
but instead severely decreased in SOX2 expressing cells
(Fig. 1a). We also investigated the expression of several
matrix metalloproteinases (MMPs) to examine possible ef-
fects on the extracellular matrix, caused by SOX2 expres-
sion. Most of the investigated MMPs were found to be
down-regulated in Caco2-SOX2 cells (Fig. 1b). We further
compared the migratory ability of Caco2 and Caco2-
SOX2 cells using Boyden transwell migration experiments.
































































































































Fig. 1 Evaluation of EMT and cellular migration in response to SOX2 expression. Caco2 cells and Caco2 cells stably transfected with SOX2 (Caco2-
SOX2) was analyzed by RT-PCR for the expression of a EMT related genes, or b MMPs. Shown is relative gene expression from three or more
independent experiments ± SD with Caco2 levels set as 1. c Cellular migration was evaluated using Boyden chamber experiments. Shown is mean
number of migrating cells ± SD from three independent experiments. Significant differences are indicated by * (P < 0.05)
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in Caco2 cells expressing SOX2 compared to Caco2 wild
type cells (Fig. 1c). Together, these results incline that
SOX2 is not a major regulator of EMT or cellular migra-
tion and invasion in our in vitro model.
SOX2 induces a stem cell state in CRC cells
Further investigations revealed that Caco2 cells express-
ing high levels of SOX2 had a lower proliferative rate
(Fig. 2a), were less adherent and displayed a spheroid
growth pattern compared to Caco2 wild type cells that
were more confluent (Fig. 2b). Accordingly, Caco2-
SOX2 cells showed decreased expression of several im-
portant adhesion molecules (Fig. 2c). Decreased prolifer-
ation and adhesion are events indicative of a cancer
stem cell state. We further analyzed cancer stem cell
markers, CD44, CD24 and CD133, associated with ag-
gressive cancer types and poor prognosis in CRC [33]
(Fig. 2d). Expression of CD44 and CD24 was found to
be significantly increased in Caco2 cells expressing
SOX2. The levels of CD133 were instead found to be de-
creased. Together, the phenotype seen in Caco2-SOX2
cells suggests that SOX2 might induce a cancer stem cell
state in CRC leading to increased aggressiveness and
poorer patient prognosis.
SOX2 is inversely associated with expression of the
intestinal epithelial cell marker CDX2
We previously found that SOX2 positive CRC tumors
more often are poorly differentiated [7]. A poor cell dif-
ferentiation is also found in tumors that loose the ex-
pression of CDX2, an intestine-specific transcription
factor essential for intestinal homeostasis and for the
maintenance of an intestinal epithelial phenotype [34].
Furthermore, loss of CDX2 has been linked to more ag-
gressive tumors and a poor outcome in CRC [25–27].












































































































Fig. 2 SOX2 induces a CSC state in CRC cells. Factors associated with a CSC state was evaluated in Caco2 cells and Caco2 cells stably transfected
with SOX2 (Caco2-SOX2). a Proliferation of cells as measured by XTT cell proliferation assay. b Morphological evaluation of cells. c Expression of
cellular adhesion molecules as evaluated by RT-PCR. Shown is relative expression with Caco2 cells set as 1. d Expression of cancer stem cell
markers as evaluated by RT-PCR. Shown is relative expression with Caco2 cells set as 1. Gene expression analyses were reproduced three times
and mean values ± SD is shown. Significant differences are indicated by * (P < 0.05)
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Caco2 and Caco2-SOX2 cells. We found that Caco2-
SOX2 cells showed significantly decreased levels of
CDX2, compared to control Caco2 cells (Fig. 3a). Fur-
thermore, we compared SW480 and SW620 CRC cell
lines, derived from a primary and metastatic tumor, re-
spectively, resected from a single patient. A high expres-
sion of SOX2 was found in the metastatic cell line, and
correlated to a significantly decreased expression of
CDX2 (Fig. 3a). We further analyzed fresh frozen tumor
tissue from 25 CRC patients by RT-PCR for the expres-
sion of SOX2 and CDX2. Generally, in tumors with a
high expression of SOX2 the levels of CDX2 were either
low or absent (Fig. 3b). Likewise, in tumors with a high
expression of CDX2, the levels of SOX2 were low or ab-
sent (Fig. 3b). These findings suggest that SOX2 expres-
sion is associated with a down-regulated expression of
CDX2.
SOX2 is associated with a down-regulated expression of
CDX2 in CRC patients
The expression of CDX2 was evaluated by immunohisto-
chemistry in a large cohort of 445 CRC patients. Nuclear
CDX2 expression was scored in tumor tissue as; less
than 5 % positive cells, 5–50 % positive cells or, more
than 50 % positive cells. Representative images of the
immunohistochemical stainings of CDX2 can be found
in Fig. 4a. In total, 43.4 % of patients showed less than
50 % CDX2 positive tumor nuclei, and of those 14.4 %
showed a close to complete lack of CDX2 expression
(<5 % positive cells) (Table 1). A down-regulated expres-
sion of CDX2 was more often found in right sided tu-
mors (P < 0.001) and tumors of higher stage (P < 0.001)
(Table 1). Furthermore, loss of CDX2 expression was
significantly associated with poorly differentiated tumors
(P < 0.001) (Table 1). In survival analyses, a down-
regulated expression of CDX2 correlated, in a stepwise
manner, to a poor patient survival (Log-rank P < 0.001)
(Fig. 4b). The prognostic importance of CDX2 down-
regulation stayed significant in multivariable Cox regres-
sion analyses adjusting for stage, age, sex, localization
and grade (for patients with 5–50 % CDX2 (HR = 1.54,
95 % CI 1.04–2.28, P = 0.031) and for patients with <5 %
CDX2 (HR = 2.45, 95 % CI 1.50–4.01, P < 0.001)).
When looking at molecular subgroups of CRC, a
down-regulated expression of CDX2 was closely linked
to CIMP-high (P < 0.001), MSI (P < 0.001) and BRAF
mutated tumors (P < 0.001) (Table 2). Furthermore, a
down-regulated expression of CDX2 was more often
found in SOX2 positive tumors (P < 0.001) (Table 2). Of
the SOX2 positive tumors, 73.9 % had less than 50 %
CDX2 positive tumor cells, and of these 32.6 % had less






















































































Fig. 3 SOX2 is associated with down-regulated expression of CDX2. a Caco2, Caco2-SOX2, SW480 and SW620 cells were analyzed by RT-PCR for
the expression of CDX2 and SOX2. Shown is relative gene expression from three independent experiments ± SD with Caco2 or SW480 levels set
as 1. Significant differences are indicated by * (P < 0.05). b RNA from fresh frozen tumor tissue from 25 CRC patients was analyzed by RT-PCR for
the expression of SOX2 and CDX2. Shown is normalized gene expression
Lundberg et al. BMC Cancer  (2016) 16:471 Page 6 of 11
SOX2 positive tumors with a down-regulated expres-
sion of CDX2 (<50 % positive cells) had a worse progno-
sis than SOX2 positive tumors with retained CDX2
expression (>50 % positive cells) (Fig. 4c), suggesting
that a part of the negative role of SOX2 on prognosis
might be through down-regulation of CDX2. 40.2 % of
the SOX2 negative tumors also showed a down-
regulated expression of CDX2 (less than 50 % positive
cells) (Table 2). In SOX2 negative tumors, CDX2 down-
regulation also resulted in a poorer patient prognosis
(Fig. 4c), suggesting that CDX2 expression in itself is a
strong prognostic factor and likely can be regulated also
independently of SOX2.
Discussion
Expression of SOX2 is associated with a poor patient
prognosis in CRC, but so far the molecular mechanisms
have not been fully elucidated. Here we have studied the
functional role of SOX2 in CRC. Using an in vitro cell
culture model, we could show that expression of SOX2
was associated with a cellular stem cell state and de-
creased expression of the intestinal epithelial marker
CDX2. The correlation of SOX2 expression and a de-
creased expression of CDX2 could further be verified in
our patient cohort. We also found that decreased ex-
pression of CDX2 correlated to a poor patient survival,
and that SOX2 expressing tumors with a down-
regulated CDX2 expression had a worse patient progno-
sis compared to those with a retained CDX2 expression,
suggesting that a part of the negative role of SOX2 on
prognosis might be through down-regulation of CDX2.
In a previous report by Han et al., a role for SOX2 in
EMT and increased migration and invasion in CRC was
presented [9]. In our in vitro model expressing SOX2,
we found that SOX2 did not increase the migratory ef-
fect of tumor cells and was not a major regulator of
Fig. 4 Evaluation of CDX2 expression in CRC. a Representative images of immunohistological stainings of CDX2 in human CRC tissue specimens;
normal colon epithelium and CRC with <5 % expression, 5–50 % expression and >50 % expression of CDX2. b Kaplan-Meier survival analyses of
CDX2 expression in CRC. c Kaplan-Meier survival analyses in subgroups of CRC defined as SOX2 positive or negative, and CDX2 < 50 % expression
and >50 % expression. Log-rank tests were used to calculate P-values
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EMT. Instead, our cells expressing SOX2 showed a
lower proliferative rate, were less adherent and displayed
a more spheroid growth pattern compared to wild type
cells. These are all characteristics of CSCs. CSCs possess
stem cell-like features, like the ability of self-renewal and
multi-lineage differentiation and they have been pro-
posed to retain their tumorigenic capacity and to be the
cells responsible for initiation, maintenance and spread-
ing of the tumor [35, 36]. Sphere-forming CSCs have
been shown to be more aggressive (metastatic) in vivo
than adherent cells [37]. Stem cells divide more slowly
than differentiated cells, and the quiescent slow-cycling
phenotype seen in CSCs probably plays a role in tumor
recurrence as well as resistance to treatment [38, 39]. A
possible SOX2 induced CSC state in our in vitro model
could thereby be one explanation to the decreased sur-
vival seen in patients with SOX2 positive tumors. In line
with this hypothesis, cancer cells expressing SOX2
showed an increased expression of the stem cell markers
CD24 and CD44. The expression of the stem cell marker
CD133 was instead decreased. CD24 has previously been
shown to be regulated by SOX2 [5]. CD44 has been
identified as a potential CSC marker in CRC [40] and
has also been shown to be a more selective colon CSC
marker than CD133 since decreased expression of
CD44, but not CD133, has been shown to reduce both
clonal formation and tumor formation [41]. Other stud-
ies have also indicated that CD133 might not be a good
CSC marker in CRC, since knocking-down the gene ex-
pression of CD133 does not induce cellular differenti-
ation in CRC [42], and both CD133 positive and CD133
negative CRC subpopulations are capable of tumor initi-
ation [43]. CD44 is also the main receptor of the ECM
component hyaluronan [44], and it has been shown that
expression of CD44 on tumor cells correlate with cancer
cell adhesion to endothelial cells and also with metasta-
sis [45]. In a previous study, a cluster of stem-like fac-
tors, including SOX2 and CD44, identified patients with
a worse prognosis [46]. We plan to further investigate
the role of SOX2 in cancer stem cell differentiation and
tumor progression. In few previous studies, the sug-
gested role of SOX2 in cancer stem cell differentiation
has, in difference to our study, at least partly been linked
to EMT related factors [14, 15]. Further studies of the
Table 1 CDX2 expression in relation to clinicopathological
characteristics in CRC
CDX2 expression
<5 % 5–50 % >50 % P valuea
Frequencies, n (%) 62 (14.4) 125 (29.0) 244 (56.6)
Sex, n (%) 0.667
Male 33 (14.3) 63 (27.3) 135 (58.4)
Female 29 (14.5) 62 (31.0) 109 (54.5)
Age, n (%) 0.275
≤59 years 16 (21.1) 18 (23.7) 42 (55.3)
60–69 years 16 (14.7) 29 (26.6) 64 (58.7)
70–79 years 20 (12.9) 54 (34.8) 81 (52.3)
≥80 years 10 (11.0) 24 (26.4) 57 (62.6)
TNM stage, n (%)b <0.001
I 2 (3.0) 21 (31.8) 43 (65.2)
II 19 (11.2) 36 (21.3) 114 (67.5)
III 17 (19.3) 32 (36.4) 39 (44.3)
IV 24 (24.2) 33 (33.3) 42 (42.4)
Localization, n (%)b <0.001
Right colon 41 (29.5) 27 (19.4) 71 (51.1)
Left colon 9 (7.1) 39 (30.7) 79 (62.2)
Rectum 12 (7.5) 59 (36.6) 90 (55.9)
Grade, n (%)b <0.001
Highly to moderately
differentiated
13 (6.3) 45 (22.0) 147 (71.7)
Moderately to poorly
differentiated
49 (22.5) 80 (36.7) 89 (40.8)
aχ2 test
bThe following numbers of missing cases were present: TNM stage, 9;
localization, 4; grade, 8
Table 2 CDX2 expression in relation to molecular characteristics
in CRC
CDX2 expression
<5 % 5–50 % >50 % P valuea
Frequencies, n (%) 62 (14.4) 125 (29.0) 244 (56.6)
MSI screening status, n (%)b <0.001
MSI 27 (41.5) 14 (21.5) 24 (36.9)
MSS 33 (9.4) 108 (30.8) 210 (59.8)
CIMP status, n (%)b <0.001
CIMP-negativec 8 (3.8) 66 (31.1) 138 (65.1)
CIMP-lowc 25 (15.6) 46 (28.8) 89 (55.6)
CIMP-highc 29 (52.7) 10 (18.2) 16 (29.1)
BRAFV600E, n (%)b <0.001
wild type 27 (7.4) 110 (30.3) 226 (62.3)
mutated 35 (58.3) 11 (18.3) 14 (23.3)
KRAS (codon 12, 13), n (%)b 0.027
wild type 55 (16.2) 88 (26.0) 196 (57.8)
mutated 7 (8.2) 33 (38.8) 45 (52.9)
SOX2 expression, n (%)b <0.001
SOX2 negative 44 (12.3) 100 (27.9) 215 (59.9)
SOX2 positive 15 (32.6) 19 (41.3) 12 (26.1)
Abbreviations: MSI microsatellite instability, MSS, microsatellite stable, CIMP
CpG island methylator phenotype (according to an eight-gene CIMP panel)
aχ2 test
bThe following numbers of missing cases were present: MSI screening status,
15; CIMP status, 4; BRAF V600E, 8; KRAS, 7; SOX2 expression, 26
cCIMP negative, no promoter hypermethylation; CIMP low, one to five genes
methylated; CIMP high, six to eight genes methylated
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functional role of SOX2 in human cancers are required
to clarify these differences.
In our previous study of SOX2 expression in CRC, we
have shown that poorly differentiated tumors more often
are SOX2 positive [7]. Poorly differentiated tumors have
also been associated with decreased expression of the in-
testinal epithelial marker CDX2 (reviewed in [47]).
Therefore, we were interested in studying the expression
of CDX2 in correlation to expression of SOX2. Two dif-
ferent cell lines expressing SOX2 showed a decreased
expression of CDX2 compared to the wild type cell lines.
RT-PCR analyses of fresh frozen tumor tissue verified
that tumors with a high expression of SOX2 had low or
absent expression of CDX2. When analyzing the expres-
sion of CDX2 by immunohistochemistry in our patient
cohort, we found that SOX2 positive tumors were highly
associated with a decreased expression of CDX2; 73.9 %
of the SOX2 positive tumors had less than 50 % CDX2
positive tumor cells, and of these 32.6 % had less than
5 % positive cells. Together these results suggest that ex-
pression of SOX2 is correlated to a down-regulated ex-
pression of CDX2.
A down-regulated expression of CDX2 in CRC has
previously been linked to subgroups of tumors defined
as CIMP-high, MSI, and BRAF mutated although results
are still inconclusive (reviewed in [47]). In our cohort, a
down-regulated expression of CDX2 was closely linked
to CIMP-high (P < 0.001), MSI (P < 0.001) and BRAF
mutated tumors (P < 0.001) (Table 2), strengthening pre-
viously published findings. This finding is also in line
with our previous results that SOX2 is partly regulated
by BRAF [7]. Down-regulated expression of CDX2 was
also correlated to a poor patient prognosis in our cohort,
similar to other reports in CRC [25–27]. In our study,
the prognostic importance of CDX2 remained significant
in multivariable analyses adjusted for stage and other
confounders, suggesting that CDX2 is a powerful prog-
nostic factor in CRC. When combining the expression of
CDX2 and SOX2 we found that SOX2 positive tumors
with a decreased expression of CDX2 had a worse pa-
tient prognosis compared to those with a retained CDX2
expression, indicating that at least a part of the negative
role of SOX2 on prognosis might be through down-
regulation of CDX2. This subgroup, showing SOX2 ex-
pression but a down-regulated expression of CDX2, has
previously been shown to predict a worse patient out-
come in gastric cancer [48]. Since decreased expression
of CDX2 also could be seen in SOX2 negative tumors,
we speculate that CDX2 can be down-regulated both by
SOX2 dependent and SOX2 independent mechanisms.
SOX2 expression is often seen only in a part of the
tumor, and since SOX2 expression is analyzed in just
one tissue section per tumor [7], the number of SOX2
positive tumors in our patient cohort may be
underestimated and some of the SOX2 negative tumors
with down-regulated expression of CDX2 might actually
be SOX2 positive. However, likely there are also other
events involved.
CDX2 has been suggested to be a target gene of the
Hippo pathway in CRC [49]. The Hippo pathway nor-
mally plays critical roles in cell proliferation, growth and
apoptosis, but when deregulated it is instead involved in
initiation and progression of tumors [50, 51]. Studies
have also suggested that SOX2 is involved in the deregu-
lation of the Hippo pathway [52, 53], and therefore we
speculate that the SOX2 mediated down-regulation of
CDX2 might partly be through this pathway. Kuzmichev
et al. have further shown that SOX21 can repress the ex-
pression of CDX2 in CRC, and that SOX21 is induced
by SOX2 [54]. SOX21 might therefore be another pos-
sible pathway that SOX2 utilizes to regulate the expres-
sion CDX2. The mechanisms behind the regulation of
CDX2 expression by SOX2 will be further investigated.
Conclusions
Using an in vitro cell model, we found that SOX2 in
CRC induces a CSC state with down-regulated expres-
sion of the intestinal epithelial transcription factor
CDX2. In our patient cohort, the expression of SOX2
was highly and significantly associated with a down-
regulated expression of CDX2. Furthermore, SOX2 ex-
pressing tumors with down-regulated expression of
CDX2 had a particularly poor prognosis. We suggest
that the poor prognosis seen in patients with SOX2 posi-
tive tumors is at least partly mediated through down-
regulated expression of CDX2.
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